Imatinib-induced exacerbation of psoriasis in a patient with recurrent dermatofibrosarcoma protuberans: A case report and review of the literature

详细信息    查看全文

• 作者：Hsiao-Yu Lin¹ ; ^a ; Chung-Hao Hsu² ; ^a ; Shih-Tsung Cheng¹ ; ² ; Chung-Hsing Chang¹ ; ² ; ^{miriamchangch@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：dermatofibrosarcoma protuberans (DFSP) ; imatinib ; psoriasis ; tyrosine kinase inhibitor
• 刊名：Dermatologica Sinica
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：34
• 期：1
• 页码：26-28
• 全文大小：1108 K

文摘

Imatinib, a tyrosine kinase inhibitor, is the current preferred agent for the treatment of unresectable or metastatic dermatofibrosarcoma protuberans (DFSP). We present the first case report with exacerbated psoriasis during imatinib treatment for recurrent DFSP. The condition of a 63-year-old man with a history of psoriasis vulgaris for 17 years was controlled well by topical calcipotriol. He suffered from a recurrent DFSP, and the molecular pathology analysis showed OL1A1–PDGFB fusion transcript. Imatinib (400 mg daily) was commenced after surgical excision, and 4 weeks later he developed generalized psoriasis that was poorly controlled by regular treatment. After discontinuation of imatinib, combined with systemic antihistamine and topical corticosteroid, the lesions improved in 8 weeks. We further reviewed the literature to characterize the imatinib-induced psoriasis.